Trials / Conditions / Chronic Lymphocytic Leukaemia

Chronic Lymphocytic Leukaemia

19 registered clinical trials studyying Chronic Lymphocytic Leukaemia — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failur NCT06651970	AstraZeneca	Phase 4
Recruiting	A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038	AstraZeneca	Phase 1 / Phase 2
Recruiting	Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufacture NCT06357754	Bristol-Myers Squibb	—
Unknown	First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NCT04763083	NovalGen Ltd.	Phase 1
Recruiting	Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893	Merck Sharp & Dohme LLC	Phase 2
Completed	Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib NCT03582098	Gilead Sciences	—
Completed	BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia NCT02933320	Cancer Research UK	Phase 1 / Phase 2
Unknown	Tissue Collection for Biomarkers Determining Resistance to Ibrutinib NCT02267590	Royal Marsden NHS Foundation Trust	—
Completed	A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies NCT01805375	Cancer Research UK	Phase 1
Completed	Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers NCT01597219	University College, London	Phase 2
Completed	Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participan NCT01659255	Gilead Sciences	Phase 1
Unknown	A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Tre NCT01678430	University of Liverpool	Phase 3
Terminated	R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic NCT01446900	European Institute of Oncology	Phase 2
Completed	Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders NCT01832597	Gruppo Italiano Studio Linfomi	—
Terminated	RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial NCT01127542	The Christie NHS Foundation Trust	Phase 2
Withdrawn	R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia NCT00504491	CABYC	Phase 2
Completed	A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia NCT00457782	Kyowa Kirin Co., Ltd.	Phase 1
Terminated	Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) NCT00751296	University Health Network, Toronto	Phase 2
Completed	A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients Wi NCT00292760	Royal Marsden NHS Foundation Trust	Phase 2